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Abstract
Background: Immune checkpoint inhibition and in particular anti-PD-1 immunotherapy have revolutionized the
treatment of advanced melanoma. In this regard, higher tumoral PD-L1 protein (gene name: CD274) expression is
associated with better clinical response and increased survival to anti-PD-1 therapy. Moreover, there is increasing
evidence that tumor suppressor proteins are involved in immune regulation and are capable of modulating the
expression of immune checkpoint proteins. Here, we determined the role of p53 protein (gene name: TP53) in
the regulation of PD-L1 expression in melanoma.
Methods: We analyzed publicly available mRNA and protein expression data from the cancer genome/proteome
atlas and performed immunohistochemistry on tumors with known TP53 status. Constitutive and IFN-ɣ-induced
PD-L1 expression upon p53 knockdown in wildtype, TP53-mutated or JAK2-overexpressing melanoma cells or in
cells, in which p53 was rendered transcriptionally inactive by CRISPR/Cas9, was determined by immunoblot or
flow cytometry. Similarly, PD-L1 expression was investigated after overexpression of a transcriptionally-impaired
p53 (L22Q, W23S) in TP53-wt or a TP53-knockout melanoma cell line. Immunoblot was applied to analyze the IFN-
ɣ signaling pathway.
Results: For TP53-mutated tumors, an increased CD274 mRNA expression and a higher frequency of PD-L1 positivity
was observed. Interestingly, positive correlations of IFNG mRNA and PD-L1 protein in both TP53-wt and -mutated
samples and of p53 and PD-L1 protein suggest a non-transcriptional mode of action of p53. Indeed, cell line experiments
revealed a diminished IFN-ɣ-induced PD-L1 expression upon p53 knockdown in both wildtype and TP53-mutated
melanoma cells, which was not the case when p53 wildtype protein was rendered transcriptionally inactive or by
ectopic expression of p53L22Q,W23S, a transcriptionally-impaired variant, in TP53-wt cells. Accordingly, expression of
p53L22Q,W23S in a TP53-knockout melanoma cell line boosted IFN-ɣ-induced PD-L1 expression. The impaired PD-
L1-inducibility after p53 knockdown was associated with a reduced JAK2 expression in the cells and was almost
abrogated by JAK2 overexpression.
Conclusions: While having only a small impact on basal PD-L1 expression, both wildtype and mutated p53 play
an important positive role for IFN-ɣ-induced PD-L1 expression in melanoma cells by supporting JAK2 expression.
Future studies should address, whether p53 expression levels might influence response to anti-PD-1 immunotherapy.
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Background
Antibodies directed against the cytotoxic T-lymphocyte-
associated antigen 4 (CTLA-4) receptor or programmed
cell death-1 (PD-1) receptor have revolutionized the
systemic therapy of advanced melanoma [1]. Indeed, with
these immunotherapeutic approaches durable responses
in the treatment of metastatic melanoma have been
achieved for the first time [2–4]. In the first-line setting,
response rates to CTLA-4 or PD-1 blockade range be-
tween 10 and 19% or 40–45%, respectively [5, 6]. More-
over, when both antibodies are combined, response rates
increase up to 61% [5]. Since these therapies, especially in
case of combination, may be accompanied by major,
possibly even life-threatening side effects, much effort is
being spent on identifying predictive biomarkers. So far,
the most commonly used predictor of therapeutic re-
sponse to PD-1 blockade is the expression of pro-
grammed-death-ligand 1 (PD-L1), a ligand of PD-1, on
tumor cells. PD-L1 (also denoted as B7-H1) is encoded by
the CD274 gene and is one of the two known ligands for
PD-1, a costimulatory molecule that negatively regulates
T-cell immune responses [7]. Notably, PD-L1 positivity (>
5% or > 1% of tumor cells positive for PD-L1 staining) is
associated with a better overall response rate (ORR),
progression free survival (PFS) and overall survival (OS) to
anti-PD-1 immunotherapies [3, 4, 6, 8–10].
PD-L1 expression is inducible in many cell types, and
increased expression has been observed in several tumor
entities including melanoma, non-small cell lung cancer
(NSCLC) and renal cell carcinoma. The interaction of
cancer cell PD-L1 with PD-1 on cytotoxic T-lympho-
cytes (CTL) results in diminished T-cell killing [11, 12].
Possible mechanisms include suppressed T-cell prolifer-
ation and T-cell activation [13], induction of T-cell
apoptosis [14] and also differentiation of CD4+ T-cells
into FOXP3+ regulatory T-cells [15].
Various mechanisms have already been described that
regulate PD-L1 expression in an often cell type-
dependent manner [16]. Upregulation in tumor cells can
be due to constitutively active oncogenic signaling path-
ways (referred to as innate immune resistance); although
for melanoma cell lines PD-L1 expression levels were
variable and independent from any driver mutation in
MAPK or PI3K pathway [11, 17]. In addition, PD-L1
expression may occur in response to tumor-targeting
immune cells that release interferon (IFN)-ɣ upon recog-
nition of their cognate antigen expressed by cancer cells.
PD-L1 expression on cancer cells subsequently inhibits
PD-1-positive T-cells, a process known as adaptive
immune resistance [11, 12]. IFN-ɣ signals through the
canonical type II interferon receptor pathway [12, 18].
When IFN-ɣ binds to the IFN-ɣ receptor, JAK2 is
activated by autophosphorylation of two tyrosine resi-
dues (Tyr 1007/Tyr 1008), and then transphosphorylates
JAK1 on Tyr1022/Tyr1023. This leads to phosphorylation
of tyrosine 440 in the IFN-ɣ receptor 1 by JAK1, which
serves as recruitment site for STAT1 then allowing its
phosphorylation on Y701 by most likely JAK2 [18, 19].
Subsequently, activated STAT1 dimers accumulate in the
nucleus and act as transcription factors binding to the
GAS (interferon-gamma activated site) elements of IFN-ɣ-
inducible genes. The most important of these genes is
interferon regulatory factor 1 (IRF1), which itself acts as a
transcription factor during its ligation to IRF1-binding
site-containing promoters like the PD-L1 promoter [18,
19]. Further transcriptional factors involved in PD-L1
regulation in melanoma include MYC, hypoxia-inducible
factor-1α and 2α (HIF-1α/2α), STAT3 and NF-κB [16].
Post-transcriptionally, PD-L1 expression can be nega-
tively regulated by various microRNAs (miRNAs, miR)
such as miR-17-5p, miR-138-5p, miR-197, miR-200,
miR-424, miR-513 and miR-570 [16, 20–26]. In addition,
Cortez et al. recently demonstrated that p53 transcrip-
tional activity leads to elevated miR-34a expression,
which in turn reduced PD-L1 expression in NSCLC [27].
The main function of the tumor suppressor p53 is the
regulation of cell proliferation and the induction of
death in cells, which harbor genomic abnormalities [28,
29]. The molecular structure of p53 protein encom-
passes six domains (given residues are based on [30], but
vary between studies): the transactivation domain (TAD)
(residues 1–67), which can further be subdivided in two
TADs; the proline-rich region (residues 68–98); the
DNA-binding domain (DBD, residues 98–292); the hinge
domain (HD, residues 293–325); the oligomerization do-
main (OD, residues 326–353); and the carboxy-terminal
regulatory domain (CTD, residues 353–393). Most TP53
mutations occur in the DBD, and by impaired binding to
target gene DNA its tumor suppressor ability is often
reduced [28]. In addition of losing its tumor-suppressive
properties, stabilized mutant p53 may gain novel func-
tions (referred to as gain-of-function, GOF) [28, 29].
Those GOF are able to promote tumor progression or
produce resistance to antitumor therapies.
Since in melanoma TP53 is frequently wildtype, we
hypothesized that p53 might play a key role in repressing
PD-L1 expression in melanoma and therefore investi-
gated the role of p53 in PD-L1 regulation in melanoma.
Indeed, by conducting knockdown experiments of p53
in melanoma cell lines as well as immunohistochemistry
of PD-L1 in melanoma tissue and analyzing the cancer
genome atlas (TCGA) database, we found evidence for
p53 being involved in the regulation of PD-L1 expres-
sion. Furthermore, we observed that induction of PD-L1
by IFN-ɣ is reduced after p53 knockdown. This is partly
due to a reduction of JAK2, since ectopic JAK2 expres-
sion can largely rescue the effect of p53 knockdown on
IFN-ɣ induced PD-L1 expression.
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Material and methods
Cell lines, reagents and treatment regimens
We studied well-characterized melanoma cells from the
NCI-60 panel that were TP53-wildtype (wt), i.e. LOX-
IMVI, M19-MEL, MALME-3M, SK-MEL-5, UACC-62,
UACC-257, or TP53-mutated, i.e. M14, MDA-MB-435,
SK-MEL-2 and SK-MEL-28. Furthermore, we used self-
established TP53-mutated melanoma cell lines MS149
(p53 Q199*) and MS186 (p53 E154K). The two NCI-60
TP53-wt NSCLC cell lines A549 and H460 served as
controls. All melanoma NCI-60 cell lines were obtained
from ATCC. The 1205Lu melanoma cell line was originally
obtained from the Wistar Institute, and the TP53-knockout
variant was generated by Prof. Veit Hornung, Bonn/Mun-
ich, Germany, and kindly provided by co-author Markus
Heppt, Munich.
Cell lines were cultured in RPMI-1640 with 10% fetal
bovine serum, 100 U/ml penicillin and 0.1 mg/ml strepto-
mycin (all from Sigma-Aldrich, Darmstadt, Germany) at
37 °C with 5% CO2. For IFN-ɣ stimulation, we used a
concentration of 200 IU/ml (ImmunoTools, Friesoythe,
Germany) for up to 48 h. Cell lines were regularly tested
for mycoplasma contamination.
Lentiviral transduction and generation of small hairpin
RNAs
For knockdown experiments we transduced cells with an
antibiotic-selectable (zeocin or blasticidin), doxycycline
(Dox)-inducible lentiviral small hairpin (sh) RNA vector.
These vectors are based on a previously described sys-
tem and the sequence is deposited (Accession number
MH749464) [31]. The TP53 targeting sequences used
were 5′-GAC TCC AGT GGT AAT CTA CT-3′ or 5′-
CAC CAT CCA CTA CAA CTA CAT-3′ (in the con-
firmation experiments). A scrambled shRNA sequence
(scr) served as control. Lentiviral transduction was per-
formed as described before [32] and knockdown efficacy
was determined by immunoblot. Cells containing doxy-
cycline-inducible p53 or scr shRNA were incubated with
doxycyline (1 μg/ml) for 6 days.
CRISPR/Cas mediated p53 inactivation
CRISPR/Cas technology was used to render wt p53
transcriptionally inactive by introducing deletions in the
DBD/HD region. To achieve p53 inactivation, cells were
transducted with a lentiviral system consisting of Dox-
inducible Cas9 (pCW-Cas9 was a gift from Eric Lander
& David Sabatini, Addgene plasmid # 50661) and lenti-
guide for gRNA expression (lentiGuide-Puro was a gift
from Feng Zhang, Addgene plasmid # 52963). Used
guides were 5′-CAT GTG TAA CAG TTC CTG CA-3′
(exon 7) and 5′-GTG AAA TAT TCT CCA TCC AG-3′
(exon 9) for LOX-IMVI and 5′-AGA TTA CCA CTA
CTC AGG AT-3′ (exon 8) and 5′-GGA GAG GAG
CTG GTG TTG TT-3′ (exon 9) for UACC-62, respect-
ively. Exon 7 and 8 encode amino acids belonging to the
DBD, while exon 9 contributes amino acids to the HD.
These two cell lines contained a GFP based p53 reporter
construct to measure p53 activity, as previously de-
scribed [33].
Ectopic JAK2 and p53L22Q,W23S expression
JAK2 expression plasmid (pUNO1-hJAK2, Invivogen, San
Diego, CA, USA) was kindly provided by Prof. Annette
Paschen (Dept. of Dermatology, University Hospital Essen,
Germany) and cloned into a pCDH-based lentiviral vector.
Two melanoma cell lines (M19-MEL, UACC-62), already
containing the zeocin-selectable, Dox-inducible p53 or scr
shRNA, were transduced with this vector. JAK2 expres-
sion was confirmed by immunoblotting.
For inducible ectopic expression of an p53 variant se-
verely compromised for transactivation we mutagenized
a pCW-based vector encoding a Dox-inducible flag-HA-
tagged TP53-wt at positions 22 and 23 to generate
p53L22Q,W23S using the QuickChange Lightning Site-di-
rected Mutagenesis kit (Agilent, Frankfurt, Germany)
[34]. Two TP53-wt melanoma cell lines (M19-MEL,
UACC-62) as well as a TP53-knockout melanoma cell
line 1205Lu were transduced with this lentiviral vector.
Immunoblotting
Total cellular proteins were extracted at 4 °C using
erythrocytes lysis buffer (ELB) containing protease inhib-
itors (Roche, Basel, Switzerland). Proteins (10–20 μg)
were resolved on 8–12% SDS–polyacrylamide gels and
transferred to Amersham™ Protran™ Premium 0.45 μm
NC (GE Health Care Europe, Freiburg, Germany).
Immunoblots were probed with antibodies against PD-
L1 (E1L3N), JAK1 (6G4), phospho-JAK1 (Tyr1022/1023;
D7N4Z), JAK2 (D2E12), phospo-JAK2 (Tyr1008; D4A8),
phospho-STAT1 (Tyr701; 58D6; all by Cell Signaling
Technology, Boston, MA, USA), STAT1 (10C4B40),
phospho-STAT1 (S727; A15158B), IRF-1 (13H3A44; all
by BioLegend, San Diego, CA, USA), monoclonal p53
(DO-1; Santa Cruz Biotechnology, Dallas, TX, USA) or
polyclonal p53 (#9282; Cell Signaling Technology). ß-
tubulin (TUB2.1) or ß-actin (AC-15; both Sigma-Aldrich)
served as loading control.
Flow cytometry
Adherent cells were detached using 0.02% ethylenedi-
aminetetraacetic acid (EDTA) in phosphate buffered sa-
line (PBS). After washing them with 0.1% bovine serum
albumin (BSA; all from Sigma-Aldrich) in PBS, cells
were incubated with PD-L1 APC antibody (29E.2A3, 1:
20; BioLegend) or with HLA-ABC (MHC class I) APC
antibody (W6/32; 1:50; ImmunoTools) for 20 min on
ice. After washing twice with 0.1% BSA in PBS cells were
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analyzed with the BD FACS Canto. Non-viable cells
were excluded using 7-Amino Actinomycin D (7-AAD;
BD Biosciences, Franklin Lakes, NJ, USA).
Immunohistochemistry
All analyzed samples were collected from patients who
received treatment at the Department of Dermatology at
the University Hospital Würzburg between November
2014 and July 2016. Written informed consent was ob-
tained from each patient.
TP53-mutation status was determined by next generation
sequencing (for detailed information on library preparation
and sequencing, please refer to Appenzeller et al. [35]).
Four μm-sections of paraffin-embedded primary and
metastatic tumors were dried at 75 °C for 20min and then
treated twice with xylol for 5min at room temperature.
Subsequently, sections were washed twice with absolute
ethanol and once with 70% ethanol followed by one rinse
with bi-distilled water. For antigen retrieval, sections were
incubated with Tris/EDTA-buffer pH 9.0 for 40min at
90 °C and then cooled down for 20min. After washing in
TBS buffer for 5min, slides were incubated with monoclo-
nal antibody against PD-L1 (E1L3N, CST, 1:200) for 40
min. Washing in TBS buffer for 5min was followed by
incubation with secondary antibodies (REAL Biotinylated
Secondary Antibodies (AB2), Dako) for 30min. Samples
were briefly washed with TBS buffer again, then incubated
in peroxidase-blocking solution for 5min, streptavidin
peroxidase for 25min, CHROM AEC/H2O2 substrate
solution for 15min, automation hematoxylin histological
staining reagent (all from Dako) for 5 min, and cleansed
with bi-distilled water. Between every incubation step,
slides were washed with TBS buffer.
Analysis of the cancer genome atlas (TCGA)
TCGA data (http://cancergenome.nih.gov/) were retrieved
and analyzed by software R with different packages [36].
In this regard, RNAseq and miRNA data for the cases of
patients diagnosed with cutaneous melanoma, were down-
loaded and prepared with the package “TCGAbiolinks”
[37]. Mutational data of TP53 (i.e. missense, truncated,
frameshift, splice mutations and homozygous deletions)
was downloaded from cBioPortal and prepared by the
package “maftools” [38]. Reverse phase protein array
(RPPA) was obtained from the cancer proteome atlas
(TCPA) [39]. For mRNA expression the transcripts per
million (TPM) values, for miRNA the reads per million
(RPM) and for the RPPA data the level 4 data generated
by replicate-based method processing was extracted. Each
data set was log2-transformed after adding the value 1 for
TPM and RPM and 5.99 for RPPA. The mRNA and
miRNA data were available for 447, the mutational data
for 347 and the RPPA for 354 individual cases. All data
were available for a cohort of 262 cases. For correlation
analysis, the mRNA and miRNA datasets extracted
from the RNAseq data available from the TCGA data-
base was first restricted to those genes, which had at
least 1 TPM (for correlation with genes) or at least 1
RPM (for correlation with miRNA) in 20% of the 447
cases using the R-package edgeR [40]. Subsequently,
CD274 mRNA expression was correlated to either the
expression of the remaining genes or miRNA using the
built in spearman correlation and loop function of R.
Real-time PCR for quantification of TP53, CD274 and JAK2
mRNA expression
mRNA isolation, cDNA transcription and RT-qPCR with
RPLP0 as endogeneous control was performed as de-
scribed before [41]. Cells were treated for 6 days with
doxycycline in the absence or presence of IFN-ɣ for the
last 2 days. Primers used to detect the expression of the
respective gene of interest by SYBR green assay were the
following: TP53_fw: GAG GTT GGC TCT GAC TGT
ACC; TP53_rv: TCC GTC CCA GTA GAT TAC CAC;
JAK2_fw: CAG GCA ACA GGA ACA AGA TG; JAK2_rv:
CCA TTC CCA TGC AGA GTC TT; CD274_fw: CAT
CTT ATT ATG CCT TGG TGT AGC A; CD274_rv:
GGA TTA CGT CTC CTC CAA ATG TG; RPLP0_fw:
CCA TCA GCA CCA CAG CCT TC; RPLP0_rv: GGC
GAC CTG GAA GTC CAA CT. Relative expression was
calculated by the ΔΔCq method with the cells treated
without doxycycline and IFN-ɣ serving as calibrator [42].
Statistics
Statistical analysis was performed with R. Graphs were
prepared with “ggplot2” [43]. Expression data between
groups were compared by the Wilcoxon–Mann–Whitney
test. Relations between two genes were calculated by
linear regression. Correlations of genes, miRNA and
protein expressions was calculated by Spearman correl-
ation on filtered data (> 1 TPM or > 0 RPM, respect-
ively, in at least 20% of cases). The factors with the best
correlation estimate values were then depicted as heat-
map generated with the package “ComplexHeatmap”
[44] using Spearman as clustering distance and ward. D
as clustering method for the factors. A p value < 0.05
was regarded significant. Gene enrichment analysis was
performed using PANTHER overrepresentation test
(version 13.1, released 2018.02.03) and Fisher test
statististics [45, 46]. FCM data and relative mRNA ex-
pression (log2 transformed) were depicted and analyzed
by Prism 7 (Graphpad) using a paired T-test.
Results
TP53-mutated melanoma present higher CD274 mRNA
expression levels
To allow for an easier discrimination between mRNA
and protein in our manuscript, we refer to the official
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gene names for mRNA (TP53 and CD274) and to the
widely-used molecule names p53 and PD-L1 (CD274)
for protein expression.
Cortez et al. [27] analyzed NSCLC data from TCGA
and reported significantly higher CD274 mRNA levels in
TP53-mutated NSCLC than in wt counterparts. Further-
more, they revealed a statistically inverse correlation
between TP53 and CD274 mRNA for the total cohort of
lung adenocarcinoma cases. To test a possible correl-
ation between TP53 and CD274 in melanoma, we ana-
lyzed TCGA skin cutaneous melanoma (SKCM) data.
To this end, also for melanoma CD274 mRNA levels
were significantly higher in TP53-mutated than in TP53-
wt samples (Fig. 1a; p = 0.0181; Mann-Whitney).
In a next step, we performed immunohistochemistry
for PD-L1 on 81 primary and metastatic melanoma
samples with known TP53-mutation status, which has
been determined by next generation sequencing before
[34]. Regarding PD-L1 staining, it is common practice to
use a threshold of either 1% or 5% of stained tumor cells
to classify tumor samples [3, 4, 6, 8, 9]. Here we scored
samples with > 1% stained tumor cells as PD-L1-positive.
Noteworthy, 4/7 (57%) of TP53-mutated samples but
only 14/74 (19%) of TP53-wt samples (p = 0.0401) were
PD-L1-positive (Fig. 1b; for clinical information on this
patient cohort see Additional file 1: Figure S1a).
In order to expand our investigation on PD-L1 expres-
sion in melanoma, we analyzed data obtained from the
cancer proteome atlas (TCPA) project, which collects
results from reverse phase protein array (RPPA) for dif-
ferent entities including melanoma [39]. These data did
not reveal a statistically significant difference in overall
Fig. 1 TP53-mutated melanoma show higher CD274 mRNA expression levels, and are immunohistochemically more often PD-L1 positive. a
Analysis of TCGA melanoma samples (n = 347) for differences in CD274 mRNA expression. Wilcoxon-Mann-Whitney test was used to compare
CD274 expression between TP53-wt and -mutant samples. b PD-L1 immunohistochemistry of primary and metastatic melanoma samples (n = 81).
Next-generation sequencing of the TP53 gene was performed previously. Samples harboring more than > 1% PD-L1 positive melanoma cells
were regarded as PD-L1-positive. A PD-L1 negative, and a positive metastasis are depicted. Magnification, each 400x (c, d) Samples (n = 262) were
stratified by TP53-mutation status and publicly available PD-L1 expression determined by reverse phase protein array was compared with the
Wilcoxon-Mann-Whitney test (c) and by linear regression association analysis with p53 (d). mRNA and protein data are presented on a logarithmic
scale. p < 0.05 is regarded as statistically significant. TPM, transcripts per million; wt, wildtype; mut, mutation
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PD-L1 expression levels between TP53-wt or -mutated
melanoma samples (Fig. 1c). We did, however, detect a
positive correlation between PD-L1 and p53 protein ex-
pression, which reached statistically significance only for
the TP53-wt cohort (p = 4 × 10− 13; R2 = 0.211; Fig. 1d).
miR-34a is not the key regulator of PD-L1 in TCGA skin
cutaneous melanoma
For NSCLC, p53-driven miR-34a expression was demon-
strated to be a key regulator of PD-L1 expression [27].
Since at least at the mRNA level the observed depend-
ency of CD274 on the TP53-mutational status was
similar for melanoma as for NSCLC, we analyzed the
melanoma TCGA data for miRNA and CD274 expres-
sion focusing first on miR-34a. Again, similar as for
NSCLC, miR-34a expression was significantly higher in
TP53-wt than in TP53-mutated tumors (p = 0.0181;
Additional file 2: Figure S2a), even with a small, but
significant negative association of TP53 mRNA and
miR-34a expression (p = 0.00057; R2 = 0.0395; data not
shown). However, no correlations between miR-34a and
CD274 mRNA (data not shown) nor between miR-34a
and PD-L1 protein (Additional file 2: Figure S2b) were
detected. Accordingly, neither miR-34a nor most of the
other known miR negatively affecting PD-L1 were
among the top 24 miRs correlating with CD274 mRNA
expression (Additional file 2: Figure S2c). The best cor-
relation was observed for CD274 mRNA and miR-7702
(Additional file 2: Figure S2d; p = 2 × 10− 16; R2 = 0.353),
whose expression, however, was not significantly different
between TP53-wt and -mutated tumors (Additional file 2:
Figure S2e). Indeed, a positive correlation between CD274
mRNA and miR-7702 was evident in both TP53 genotypes
(Additional file 2: Figure S2f).
Members of immune-related pathways are enriched
among the genes correlating best with CD274 mRNA
expression in TCGA dataset
So far, our results revealed an increased CD274 mRNA
expression in the TCGA data and a higher percentage of
PD-L1 positivity in TP53-mutated tumors in our cohort
of 81 samples, while overall PD-L1 expression levels
were not significantly different. We thus analyzed 6
TP53-wt and 6 TP53-mutated melanoma cell lines for
PD-L1 expression. Our immunoblot analysis revealed
that - as expected [47] - p53 expression levels were
mostly higher in mutated cell lines, but no consistent
difference in basal PD-L1 expression was evident when
stratified by TP53 status (Fig. 2a).
Hence, to identify factors, which modulate CD274
mRNA expression, we searched for the 24 genes with the
best correlation to CD274 mRNA expression (Fig. 2b). In
order to determine pathways that were overrepresented
among these 24 genes, we analyzed them with PANTHER
[45, 46]. This analysis demonstrated that the only pathways
overrepresented by the genes are immune response-related
(Fig. 2c), indicating that an ongoing immune response with
IFN-ɣ secretion and activation of the JAK/STAT pathway
might impact PD-L1 expression.
These observations prompted us to perform in vitro
experiments in order to determine the role of p53 in the
regulation of PD-L1 expression.
p53 knockdown increases basal, but negatively affects
IFN-ɣ-induced PD-L1 expression in melanoma cells
In order to directly test the impact of p53 on PD-L1
expression, we generated several cell lines with inducible
shRNA targeting TP53. Two TP53-wt NSCLC cell lines,
i.e. A549 and H460, which in another study demonstrated
increased PD-L1 expression upon p53 knockdown or
miR-34a transfection, served as positive controls [27].
Indeed, H460 cells displayed a slightly increased expres-
sion of PD-L1 upon p53 knockdown while expression
levels were unaffected in scr control cells (Fig. 3a).
Among the 6 p53 wt melanoma cells tested (LOX-
IMVI, M19-MEL, MALME-3 M, SK-MEL-5, UACC-62,
UACC-257), a modest increase of PD-L1 upon p53
knockdown was only evident for LOX-IMVI and
MALME-3M. For SK-MEL-5 there was no difference,
and because for all others melanoma lines basal PD-L1
expression levels were below the detection limit of the
immunoblot, we analyzed PD-L1 expression also by flow
cytometry. This analysis demonstrated that in all analyzed
cell lines a slight increase of PD-L1 expression was meas-
urable upon p53 knockdown which, however, was not
significant in any cell line (Additional file 3: Figure S3a).
It is known from the literature as well as apparent from
our TCGA data analysis that PD-L1 expression is modi-
fied by immune responses leading to IFN-ɣ secretion [11,
12]. We therefore analyzed the effect of p53 knockdown
on IFN-ɣ-induced PD-L1 expression. To this end, after
culture for 4 days in the absence or presence of doxycyc-
line to induce knockdown of p53, cells were additionally
treated for 48 h with IFN-ɣ, and PD-L1 expression was
determined by immunoblot or flow cytometry. As ex-
pected, IFN-ɣ did increase PD-L1 expression in all cell
lines (Fig. 3a, Additional file 3: Figure S3a). This increase
was much more pronounced than the increases observed
upon p53 knockdown. Only for SK-MEL-5 the increase
upon IFN-ɣ treatment was marginal. In the two NSCLC
cell lines, IFN-ɣ-induced PD-L1 upregulation was similar
or slightly increased upon additional p53 knockdown
(Fig. 3a, Additional file 3: Figure S3a). Surprisingly,
however, in the five melanoma cell lines (LOX-IMVI,
M19-MEL, MALME-3M, UACC-62, UACC-257) dem-
onstrating a distinct IFN-ɣ-induced PD-L1 upregulation
in our immunoblot analyses, a reduction of p53 protein
levels was accompanied by a decreased IFN-ɣ-inducible
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PD-L1 expression. Indeed, the most prominent decrease
of PD-L1-inducibilty was observed in those cell lines that
presented with the strongest PD-L1 induction upon IFN-ɣ
treatment (M19-MEL, UACC-62 and UACC-257, Fig. 3a,
Additional file 3: Figure S3a).
Since shRNA might have off-target effects, we repeated
these experiments in four melanoma cell lines with a
second TP53-targeting shRNA. Although knockdown
efficiency of this shRNA was not as good, we could still
confirm our observation that upon p53 knockdown IFN-
ɣ treatment was less effective in inducing PD-L1 expres-
sion (Additional file 3: Figure S3b).
Altogether, p53 knockdown in TP53-wildtype melan-
oma cells resulted in only a very modest increase of
basal PD-L1 expression, but clearly reduced IFN-ɣ in-
duced expression.
The extent of IFN-ɣ-inducible PD-L1 expression is
dependent on the presence of p53 protein, but not on its
transcriptional activity
Our analyses of publicly available data had revealed that
there is a positive correlation between PD-L1 and p53
expression. Further analyses demonstrated that IFNG
mRNA levels were not different between tumors with
TP53-wt or TP53-mutant status (Additional file 4: Figure
S4a). Moreover, while IFNG levels did not correlate with
p53 expression, there was a positive correlation with PD-
L1 expression for both TP53 genotypes (Additional file 4:
Figure S4b, c). Taken together, these observations suggest
that while p53 presence augments IFN-ɣ-induced PD-L1
expression, this might not dependent on its transcriptional
activity. In order to test this hypothesis, we rendered p53
transcriptionally inactive in originally TP53-wt melanoma
Fig. 2 CD274 expression correlates with genes of immune-related pathways while PD-L1 levels lack correlation with p53’s transcriptional activity.
a Immunoblot for PD-L1 and p53 expression of each six untreated TP53-wildtype and -mutated melanoma cell lines. Before lysis, cells were
cultured for at least three days. Blot is representative of two individual experiments. b Correlation of CD274 with other genes was calculated
using Spearman correlation (n = 447). Only genes with > 1 TPM in a least 20% of cases were included. The 24 best correlating genes are
presented in a “heatmap”. Expression values are presented in a spectrum of blue (small) to red (high). c Gene enrichment analysis of the 24 best
correlating genes with PANTHER overrepresentation test and Fisher test statistics depicting overrepresented pathways. Total number (#) of genes
ascribed to the respective pathway, number of genes from the top 24 genes belonging to the pathway, expected frequency, fold enrichment,
overpresentation indicated by “+”, raw p-value and false discovery rate (FDR) are given. p < 0.05 is regarded as statistically significant. TPM,
transcripts per million
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Fig. 3 (See legend on next page.)
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cells by introducing deletions in the DBD/HD using
CRISPR/Cas9 technology. These two generated melanoma
cell lines expressed truncated p53 which resulted in
diminished p53 reporter activity. The extent of PD-L1
induction following IFN-ɣ treatment was, however, not
affected (Fig. 3b).
Furthermore, we analyzed whether the effect observed
for p53 knockdown in the wildtype TP53 melanoma cell
lines could be reproduced in three TP53-mutant cell lines
(M14, SK-MEL-2, SK-MEL-28). Similar to TP53-wt melan-
oma cell lines, the reduction of p53 protein in these cells
led to an impaired induction of PD-L1 by IFN-ɣ (Fig. 3c).
The ability to activate gene transcription is among the
best-characterized properties of p53. This function is
ascribed to the two transactivation domains (TADs), and
introducing mutations at the amino acids 22 and 23 gen-
erates a p53 protein (p53L22Q,W23S) with clearly reduced
transactivation-potential [34]. Hence, to further evaluate
the role of transcriptional activity for IFN-ɣ-induced PD-
L1 expression, we transduced TP53-wt melanoma cell
lines or a TP53-knockout cell line with a vector allowing
inducible expression of p53L22Q,W23S. When expressed in
TP53-wt melanoma cell lines, PD-L1 inducibility by IFN-ɣ
was hardly affected (Fig. 3d). Importantly, however,
expression in a TP53-knockout melanoma cell line was
already associated with an increased basal PD-L1 expres-
sion, and boosted PD-L1 expression upon IFN-ɣ stimula-
tion (Fig. 3e). Thus, even when transactivation activity is
impaired, the presence of p53 can augment IFN-ɣ-induced
PD-L1 expression.
p53 knockdown leads to a reduction of JAK2, which is
associated with a delayed JAK2 and a diminished STAT1
phosphorylation by IFN-ɣ
As mentioned before, IFN-ɣ signals through the JAK-
STAT-IRF1 axis to regulate PD-L1 [18]. Notably, among
the top 24 genes whose mRNA correlated with CD274
mRNA in the TCGA SKCM data set, the best correlation
was for STAT1 (p = 2 × 10− 16; R2 = 0.584, Figs. 2c, 4a),
which translated also in a positive correlation of STAT1
mRNA and PD-L1 (p = 2 × 10− 16; R2 = 0.271, Fig. 4b).
Importantly, STAT1 activation by genotoxic agents has
been demonstrated to depend on p53 protein but not on
its transcriptional activity [48]. In this regard, STAT1 pos-
sesses two phosphorylation sites (Y701 and S727), both of
which are functionally important for efficient signaling
through the type II interferon receptor pathway [19].
STAT1 Y701 phosphorylation depends directly on acti-
vated JAK1/2, whereas STAT1 S727 phosphorylation is
fundamental for maximal ability to activate transcription
of target genes, and can be modulated by different cellular
influences [19, 49]. We first examined the effect of short
term IFN-ɣ treatment, i.e. after 5, 15, 30 or 60min, on the
JAK/STAT pathway in two melanoma cell lines. These
analyses revealed that total JAK2 and to a lesser extent
STAT1 were reduced in p53 knockdown cells. Shortly
after addition of IFN-ɣ, JAK2 became phosphorylated at
Y1008 and STAT1 at Y701 while the phosphorylation of
STAT1 at S727 was unchanged. In cells with reduced p53
levels, absolute JAK2 Y1008 phosphorylation levels were
at least at 5 and 15min lower; although the ratio of phos-
phorylated to total JAK2 was even higher due to decreased
total JAK2 levels. Similarly, although more of STAT1 is
phosphorylated at Y701, the total amount is slightly re-
duced due to accompanied decreased total-STAT1 levels
(Fig. 4c). Of note, treatment of cells with IFN-ɣ for 48 h
generally led to a decrease of JAK2 in melanoma cells,
which was even more evident in cells with p53 knock-
down (Fig. 5a). At this time point, STAT1 S727 phosphor-
ylation was reduced in p53 knockdown cells.
Ectopic JAK2 can largely restore reduced IFN-ɣ-inducible
PD-L1 expression after p53 knockdown
Besides a reduced JAK2 expression upon p53 knockdown,
we also detected within the TCGA-SKCM data a positive
correlation between CD274 mRNA and JAK2 mRNA (p =
2.2 × 10− 16; R2 = 0.459) as well as between PD-L1 and
JAK2 mRNA (p = 7.6 × 10− 10; R2 = 0.136; Figs. 5b and c).
To test, if reduction of IFN-ɣ-induced JAK2 and PD-L1
protein levels after p53 knockdown is accompanied with a
decrease of corresponding mRNAs, we performed real-
time PCR. These analyses revealed that p53 knockdown
(See figure on previous page.)
Fig. 3 Presence of p53 protein, but not its transcriptional activity determines extent of IFN-ɣ induced PD-L1 expression in melanoma. a
Immunoblot for PD-L1 and p53. NSCLC cell lines A549 and H460 served as control; all other are melanoma cell lines. IFN-ɣ treatment was for 48
h. b p53 was rendered transcriptionally inactive by introducing deletions using CRISPR/Cas9 technology and gRNA targeting exons 7 and 9 (LOX-
IMVI) or exons 8 and 9 (UACC-62), respectively. Loss of transcriptional activity was determined by expression of GFP-based p53 reporter (left
histograms; red: parental cells; blue: cells after CRISPR/Cas9 genome editing). Protein expression of p53 and PD-L1 in the absence or presence of
IFN-ɣ for 48 h was determined by immunoblot. c Immunoblot for PD-L1 and p53 in TP53-mutated melanoma cells upon shRNA-mediated p53
knockdown. Cells were treated with IFN-ɣ as their TP53-wildtyp counterparts described in (a). p53 knockdown was achieved by culturing cells in
doxycycline for 6 days. d, e Two TP53-wt melanoma cell lines (d) or a TP53-knockout cell line (e) were transduced with doxycycline-inducible
p53L22Q,W23S expression construct. Cells were incubated with doxycycline and treated with IFN-ɣ for 48 h, as described before. Expression of
indicated proteins was determined by immunoblot. Arrow (d) indicates ectopic p53 expression. Please note, that for M19-MEL (d) the ectopic p53
expression was so much stronger than the endogenous that, in those samples without doxycycline, the signal for endogenous p53 was too low
to be detected. ß-tubulin (a-d) or actin (e) served as loading controls. DOX, doxycycline. All blots are representative of two individual experiments
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had no dramatic impact on basal JAK2 or CD274 mRNA
expression levels in the 2 melanoma cell lines M19-MEL
and UACC-62. Upon stimulation with IFN-ɣ, cells dem-
onstrated enhanced JAK2 and CD274 mRNA expression.
When combined with p53 knockdown, these increases
were significantly reduced (Fig. 5d).
Based on our observations, we hypothesized that re-
duced JAK2 levels upon p53 knockdown are at least
partially responsible for the decreased IFN-ɣ-induced PD-
L1 expression. Therefore, we analyzed p53 knockdown in
two melanoma cell lines ectopically expressing JAK2. In
those cells, JAK2 levels were higher than endogenous
levels in control cells. While IFN-ɣ-induced expression of
interferon regulatory factor 1 (IRF-1) was reduced by p53
downregulation in control cells, ectopic expression of
JAK2 led to levels similar to that in control cells without
p53 downregulation. Importantly, JAK2 overexpression
largely restored IFN-ɣ-induced PD-L1 expression in p53
knockdown cells (Fig. 5e).
Discussion
p53 is a central tumor suppressor protein, which is stabi-
lized and activated following different cellular stresses in-
cluding DNA damage and replication stress provoked by
deregulated oncogenes [29]. Once activated this transcrip-
tion factor can promote cell cycle arrest, DNA repair or
apoptosis. Importantly, the specific p53 triggered response
depends on the cellular context, which includes cell type,
epigenetic state, tissue microenvironment and activating
signals [29, 50]. In particular, it has been proposed that
melanocytes (and accordingly melanocyte-derived tumor
cells) may respond differently to p53 activation because
these cells are adopted to survive even with p53 induction
by highly mutagenic UV light and by the oxidative stress
of melanin production [51].
Besides the response to DNA damage, p53 controls
many further distinct processes and plays e.g. an import-
ant role in inflammation and immune responses [52].
Indeed, p53 is directly involved in the upregulation of
Fig. 4 Correlation of STAT1 and CD274/PD-L1 in melanoma, and disturbed IFN-ɣ signaling upon p53 knockdown in melanoma cell lines. a, b
Linear regression analyses of STAT1 mRNA with CD274 mRNA (n = 347) (a) or PD-L1 protein (n = 262) (b). c LOX-IMVI and M19-MEL were
incubated in six well plates for 6 days with doxycycline for p53 knockdown and subsequently treated with IFN-ɣ for 5, 15, 30 or 60min. Effect of
treatment on the IFN-ɣ signaling pathway was analyzed by immunoblot with the indicated antibodies. ß-tubulin served as a loading control. p <
0.05 is regarded as statistically significant. DOX, doxycycline; TPM, transcripts per million
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antigen presentation via the major histocompatibility
complex (MHC) I pathway [53]. Reported mechanisms
include induction of members of the antigen processing
machinery like TAP1 or ERAP1 by wildtype p53 [54,
55]. As a result, wildtype p53 can improve MHC class I
expression and thereby promote tumor cell killing by
Fig. 5 Restoration of p53 knockdown-associated JAK2 downregulation improves IFN-ɣ-inducible PD-L1 expression. a Immunoblot of three
melanoma cell lines containing either an inducible TP53-targeting or a scr shRNA expression vector. IFN-ɣ treatment was for 48 h. b, c Linear
regression analyses of JAK2 mRNA with CD274 mRNA (b; n = 347) or PD-L1 protein (c; n = 262). d M19-MEL and UACC-62 cells containing an
inducible TP53-targeting shRNA vector were treated for 6 days with doxycycline with the last 2 days either in absence or presence of IFN-ɣ. After
RNA isolation and cDNA generation, real-time quantitative PCR was performed for determination of TP53, JAK2 and CD274 mRNA expression.
Relative expressions were calculated by the ΔΔCq method to the respective cell line sample without doxycycline and IFN-ɣ treatment. After log2
transformation, the means + SD of three independent experiments are depicted. Significant differences are indicated by stars (* < 0.05; ** < 0.01;
paired t-test). e Two melanoma cell lines containing Doxycycline-inducible p53 shRNA were transduced with a JAK2 expression construct. Control
cells and JAK2-overexpressing cells were incubated with doxycycline and treated with IFN-ɣ for 48 h as described before. Expression of indicated
proteins was determined by immunoblot. ß-tubulin served as a loading control. p < 0.05 is regarded as statistically significant. DOX, doxycycline;
scr, scramble; TPM, transcripts per million, ctrl, control. All blots are representative of two individual experiments
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cytotoxic T-lymphocytes (CTL) [53–55]. Therefore, be-
sides several other aspects of p53 biology, also immune
modulation may contribute to the impact that TP53
mutation status has on prognosis and even more on im-
munotherapy response. Indeed, TP53 mutation has been
demonstrated to be associated with poorer outcome in
melanoma patients receiving anti-CTLA-4 treatment
[56]. In another study with melanoma patients treated
by different immune checkpoint blockade therapies,
TP53 mutation was one of the factors associated with
inferior outcome [57]. In melanoma, the best known
predictor for response to anti-PD-1 therapy is the ex-
pression of PD-L1 on tumor cells [3, 4, 6, 8–10]. In this
regard, in NSCLC it has been demonstrated that p53
downregulates PD-L1 via miR-34a and thereby enhances
CTL activity [27]. We thus analyzed publically available
mRNA and protein expression data as well as own sam-
ples to investigate whether TP53 might influence PD-L1
expression in melanoma. For CD274 mRNA we obtained
similar results to those described for NSCLC, with a
higher expression level for TP53-mutated tumors and an
inverse correlation between TP53 and CD274 mRNA for
TP53 wt melanoma tumors (Additional file 1: Figure
S1b). This correlation, however, was quite weak, and the
underlying mechanism of regulation appears to be differ-
ent from that reported for NSCLC, since we could not
observe a correlation for miR-34a and CD274 mRNA in-
dicating that specific p53 activity is context-dependent
[29, 50]. Moreover, we detected a positive correlation of
p53 and PD-L1 at the protein level. When stratified by
TP53 status, PD-L1 expression levels were not different
although p53 expression was higher in TP53-mutated
tumors (data not shown). Since RPPA protein expression
data cannot distinguish between expression on tumor or
stroma cells, we analyzed a series of melanoma samples
with known TP53 status by immunohistochemistry
revealing that PD-L1 tumor cell positivity was more
frequent in TP53-mutated tumors. This observation cer-
tainly has to be confirmed in a larger cohort. Neverthe-
less, this may match the situation of primary pulmonary
lymphoepithelioma-like carcinoma, where immunohisto-
chemically p53-positive samples, which - based on their
staining pattern - were regarded as TP53-mutated, and
were also significantly more often PD-L1-positive [58].
In contrast, the TP53 mutation status did not correlate
with PD-L1 expression in colon cancer, suggesting again
diverging mechanisms of PD-L1 regulation in different
tumor types [59]. Given that our immunoblot results did
not reveal a clear correlation between TP53-mutation
status and PD-L1 baseline expression in melanoma cell
lines (Fig. 2a), and p53 knockdown only slightly influ-
enced PD-L1 baseline expression, it is unlikely that p53
has a major intrinsic effect on PD-L1 expression in
melanoma.
Accordingly, TCGA data analyses demonstrated that,
among the mRNAs best correlating with CD274 expres-
sion, only immune response-related genes were enriched.
This indicates that an ongoing immune response may
determine PD-L1 expression. Indeed, immunohistochem-
istry of many cancers revealed PD-L1 expression typically
in T-cell–rich areas of tumors, particularly at the invasive
margin, illustrating IFN-ɣ-inducible PD-L1 expression to
be more common than constitutive expression [12, 60, 61].
This in vivo observation can be reenacted by exposing
tumor cells to IFN-ɣ, thereby leading to a marked increase
of PD-L1 expression (Knol et al. [62] and Fig. 3a). Surpris-
ingly, this increase was diminished upon p53 knockdown
in melanoma cells. Importantly, decreased IFN-ɣ-induced
PD-L1 expression upon p53 knockdown was also evident
in TP53-mutated melanoma cell lines, while rendering
p53 inactive by CRISPR/Cas9 had no effect on PD-L1
inducibility. Furthermore, a histopathological study of
desmoplastic melanoma, which frequently harbor TP53
mutations, identified a significant positive correlation
between PD-L1 and p53 expression [63, 64]. Hence, pres-
ence of p53 but not its transcriptional activity appears to
be required for full IFN-ɣ-induced PD-L1 expression in
melanoma. Consistently, expression of p53L22Q,W23S, a
p53 protein with impaired transactivation activity, in the
1205Lu TP53-knockout− melanoma cell line led to a
prominent increase of IFN-ɣ-induced PD-L1 expression.
In this context, it certainly would also be interesting to
analyze the impact of p53 with GOF mutations on IFN-ɣ-
induced PD-L1 expression, an aspect we did not yet
address.
The many functions of p53 can be divided into tran-
scription-dependent and -independent activities. Indeed,
besides in the nucleus p53 can act also in the cytosol or at
the mitochondria [65]. Regarding apoptosis promotion, it
has been demonstrated that the pro-apoptotic protein Bax
can be activated by certain transcription-deficient mutant
p53 proteins [66]. As another example, genotoxic drugs
can induce STAT1 activation, a process that depends on
p53 protein but not on its transcriptional activity. This has
been demonstrated by restoring drug-induced STAT1
Y701 phosphorylation by expression of transcriptional-in-
active p53 mutants in p53-null cell lines [48]. Of note, it
has previously been demonstrated that genotoxic stress-
induced upregulation of PD-L1 is also p53-dependent in a
breast carcinoma cell line [67].
In our experiments, reduced total-STAT1, but also
STAT1 S727 phosphorylation was evident after 48 h of
IFN-ɣ-stimulation in p53 knockdown cells. Importantly,
phosphorylation of this STAT1 site is induced by various
stimuli (e.g. LPS, PDGF) besides IFN-ɣ signaling, and is
essential for maximal transcription of target genes [19,
49]. Therefore, decreased STAT1 S727 phosphorylation
through molecules beyond JAK-STAT-signaling, could
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have contributed to the diminished IFN-ɣ induced PD-
L1 expression after p53 knockdown.
Furthermore, it has been shown that inducible but not
constitutive PD-L1 expression depends on NF-κB activa-
tion in melanoma cells [68]. Interestingly, while NF-κB
and p53 often have opposing effects in cancer cells, in
human monocytes and macrophages both co-regulate
induction of pro-inflammatory genes [69].
Our real-time PCR results indicate that IFN-ɣ-induced
upregulation of JAK2 and PD-L1 is already affected at
mRNA level (Fig. 5d). This sustains our hypothesis that
p53 knockdown impairs IFN-ɣ-induced CD274 transcrip-
tion mainly through interference with the JAK-STAT
signaling pathway. Consistently, we revealed that p53
knockdown was associated with a reduction of JAK2
protein levels (Figs. 4c, 5a and d). Luo et al. recently dem-
onstrated that JAK2 knockdown in various melanoma cell
lines only diminished PD-L1, but did not substantially
change IFN-ɣ-induced MHC-I expression [70]. In con-
trast, in an NSCLC cancer cell line p53 cooperated with
IFN-ɣ to enhance the expression of surface MHC-I [54].
Naturally, we also analyzed IFN-ɣ induced MHC-I surface
expression upon p53 knockdown and noted that induction
was only slightly affected (Additional file 3: Figure S3c).
This observation is in accordance with the results of Luo
et al. and again indicates differences between melanoma
and NSCLC [70].
Conclusions
In summary, there is a tendency of higher PD-L1 expres-
sion in TP53-mutated melanoma cells. One contributing
factor might be an increased p53 expression level in these
tumors. Indeed, while our analyses demonstrate that p53
has only a minor influence on constitutive PD-L1 expres-
sion, its presence is important for IFN-ɣ-induced PD-L1
expression through the JAK-STAT-signaling pathway in
melanoma cell lines. Moreover, it does not seem to be
important whether p53 is transcriptionally active. Interest-
ingly, short-term JAK2 inhibition in a preclinical melan-
oma model did not affect immunotherapeutic responses,
while for melanoma patients inactivating JAK2 muta-
tions have already been associated with a diminished
response to anti-PD-1 directed immunotherapy [70–72].
Accordingly, future studies should analyze, whether p53
expression levels correlate with JAK2 expression in mel-
anoma, and how they affect response to anti-PD-1-based
immunotherapy.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s13046-019-1403-9.
Additional file 1: Figure S1. Clinical characteristics of patients included
in immunohistochemistry study and weak negative correlation of TP53
and CD274 in TP53-wildtype TCGA samples. (a) A total of 81 samples
were included in this analysis. ALM indicates acral lentiginous melanoma;
LMM, lentigo maligna melanoma, NM, nodular melanoma; SSM,
superficial spreading melanoma; mut, mutated; wt, wildtype. (b) Linear
regression analysis of TP53 mRNA with CD274 mRNA (n = 347) was
conducted separately for TP53-wt and -mutant samples. (JPG 1844 kb)
Additional file 2: Figure S2. miR-34a is lower expressed in TP53-mutated
tumors but does not correlate with PD-L1 protein in melanoma. (a)
Wilcoxon-Mann-Whitney test was applied to compare miR34a expression
between TP53-wt and -mutant samples. (b) Linear regression analysis was
used to analyze the relation between miR34a and PD-L1 protein. (c)
Correlation of CD274 with miRs was calculated using spearman correlation.
Only miRs with > 1 RPM in a least 20% of cases were included. The 24 best
correlating miRs are presented in a “heatmap”. Expression values are
presented in a spectrum of blue (small values) to red (high values). (d)
Linear regression analysis of miR7702 and CD274. (e) Wilcoxon-Mann-
Whitney test was applied to compare miR7702 expression between TP53-wt
and -mutant samples. (f) Linear regression analysis of miR7702 with CD274
was conducted separately for TP53-wt and -mutant samples. p < 0.05 is
regarded as statistically significant. Mut, mutated; TPM, transcripts per
millions; RPM, reads per million; wt, wildtype. (JPG 1937 kb)
Additional file 3: Figure S3. IFN-ɣ induced PD-L1 expression is reduced
after p53 knockdown in melanoma while HLA expression is hardly affected.
(a) Flow cytometry for PD-L1 expression. Presented is the PD-L1 mean
normalized to the mean of control cells cultured without DOX or IFN-ɣ for
48 h. The data are presented as the mean + s.e.m. of three independent
experiments. *p < 0.05, ns = not significant. (b) The effect of a second TP53-
targeting shRNA on IFN-ɣ-induced PD-L1 expression. Those melanoma cell
lines, which had revealed the most distinctive reduction of IFN-ɣ-induced
PD-L1 expression upon p53 knockdown by the first shRNA, were
transduced by another inducible shRNA. IFN-ɣ treatment was for 48 h. PD-
L1 and p53 expression was measured by immunoblot. ß-tubulin served as a
loading control. Blot is representative of two individual experiments. (c)
LOX-IMVI and UACC-257, transduced with the first inducible TP53-targeting
shRNA, were treated with IFN-ɣ for 48 h. MHC-I (grey) and PD-L1 (black)
expression was measured by flow cytometry. Depicted is the fluorescence
mean normalized to the mean of control cells treated neither with
doxycycline nor IFN-ɣ. The data is presented as the mean + s.e.m. of three
independent experiments. *p < 0.05, **p < 0.01, ns = not significant. p53
knockdown was achieved by culturing cells in doxycycline for 6 days in all
experiments. (JPG 1296 kb)
Additional file 4: Figure S4. No differential expression of IFN-ɣ
between TP53-genotypes, but positive correlation of IFN-ɣ and PD-L1
expression for both genotypes. (a) Wilcoxon-Mann-Whitney test was
applied to compare IFN-ɣ expression between TP53-wt and -mutant
samples. (b, c) Linear regression analysis of IFN-ɣ with p53 protein (b) or
with PD-L1 protein (c) was conducted separately for TP53-wt and
-mutant samples. p < 0.05 is regarded as statistically significant. Mut,
mutated; TPM, transcripts per millions; wt, wildtype. (JPG 591 kb)
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